2 citations
,
January 2020 in “Einstein (São Paulo)” Topical tofacitinib shows promise as a future treatment for alopecia areata.
7 citations
,
March 2023 in “Arabian Journal of Chemistry” Cepharanthine may help treat COVID-19 by targeting multiple pathways.
A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with less inflammation.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
July 2019 in “International journal of Unani and integrative medicine” Aftimoon (Cuscuta reflexa) has various health benefits, including anti-inflammatory and anticonvulsant effects.
9 citations
,
January 1999 in “Dermatology” Acyclovir can prevent rejection of skin grafts in herpes-related lip leucoderma.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
May 2021 in “Immunology and Infectious Diseases” Viruses continue to challenge human health despite medical advances.
1 citations
,
May 2023 in “Frontiers in Pharmacology” Genetic screening for NUDT15 polymorphisms is crucial for patients taking azathioprine, especially in Asians.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
January 2017 in “Brazilian Journal of Pharmaceutical Sciences” Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.
4 citations
,
August 2023 in “Biomedicine & Pharmacotherapy” Ivacaftor can protect against noise-induced hearing loss by reducing oxidative stress.
2 citations
,
April 2019 in “Journal of the American Society of Nephrology” Fluconazole might be a new treatment for a type of diabetes that affects water balance in the body.
November 2003 in “PubMed” January 2007 in “日本看護学会抄録集 成人看護1” Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
5 citations
,
January 2023 in “IDCases” Albendazole and praziquantel can cause severe side effects, especially with prolonged use or liver issues.
2 citations
,
August 2024 in “Heliyon” Metformin may help mild COVID-19 cases, while Oseltamivir, Tamoxifen, and Dexamethasone are suggested for severe cases.
December 2022 in “Revista Medicina Cutánea Ibero-Latino-Americana” JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
5 citations
,
January 2018 in “Indian Journal of Dermatology/Indian journal of dermatology” A woman got a skin rash from taking aceclofenac, which went away after she stopped the drug.
45 citations
,
April 2021 in “Current Treatment Options in Oncology” ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
1 citations
,
July 2016 in “Reactions Weekly” Finasteride can cause itching, burning, and other side effects that may not go away after treatment.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
20 citations
,
August 2010 in “The Journal of Urology” Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.
January 2019 in “Dermatologica Sinica” Dutasteride improved both hair loss and acne in two young men.
Cepharanthine and tetrandrine show promise as COVID-19 drugs.